Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03961672
Title Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements No
Sponsors OHSU Knight Cancer Institute
Indications

chronic lymphocytic leukemia/small lymphocytic lymphoma

Therapies

Duvelisib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.